Patent application number | Description | Published |
20090291078 | GLYCO-ENGINEERED ANTIBODIES - The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that • the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and • at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue. | 11-26-2009 |
20100260808 | Method for Increasing Immunoreactivity - The invention relates to an in vitro or ex vivo method for increasing the immunoreactivity of cells of the immune system, which were contacted with an antigen, said method comprising the reduction or inhibition of the Cbl-b function of said cells, thereby increasing the immunoreactivity of the cells towards the antigen. | 10-14-2010 |
20100261214 | Method for Determining ACE2 Activity - The present invention relates to a method of determining ACE2 activity, comprising the following steps: providing ACE2-binding units immobilized on a solid carrier and specific for a part of ACE2 which is not involved in the catalytic activity of ACE2; contacting the immobilized ACE2-binding units with a sample which potentially includes the ACE2, wherein the ACE2 is bound by the ACE2-binding unit; removing the non-binding portions of the sample from the ACE2 bound to the ACE2-binding units; adding a substrate of the ACE2 which is reacted by the ACE2 activity, with the reaction providing a signal; and measuring the change in the signal during a specific period of time, wherein the change can be correlated with the ACE2 activity. | 10-14-2010 |
20100310546 | ACE2 Polypeptide - The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life. | 12-09-2010 |
20100310551 | IMMUNOGENIC, MONOCLONAL ANTIBODY - The invention relates to an immunogenic antibody which comprises at least two different epitopes of a tumor-associated antigen. | 12-09-2010 |
20100316624 | TREATMENT OF FIBROSES AND LIVER DISORDERS - The present invention relates to ACE2 for the therapeutic treatment or prevention of a fibrosis or liver disorder. | 12-16-2010 |
20110020315 | TREATMENT OF INFLAMMATORY ILLNESSES WITH ACE2 - The present invention relates to ACE2 for the therapeutic treatment or prevention of inflammation. | 01-27-2011 |
20110020331 | N-GLYCOSYLATED ANTIBODY - The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity. | 01-27-2011 |
20110033524 | TREATMENT OF TUMORS - The invention provides for innovative improvements in tumour therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity. | 02-10-2011 |
20120040864 | Method for Determining the Cbl-b Expression - The present invention relates to methods of determining intracellular Cbl-b protein in cells of a sample, comprising
| 02-16-2012 |
20140010781 | SIRNA AGAINST CBL-B AND OPTIONALLY IL-2 AND IL-12 FOR USE IN THE TREATMENT OF CANCER - The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases. | 01-09-2014 |
20140099297 | ACE2 POLYPEPTIDE - The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life | 04-10-2014 |